Fostemsavir: a first-in-class HIV-1 attachment inhibitor

Purpose of review Fostemsavir is a recently Food and Drug Administration-approved HIV-1 attachment inhibitor that binds to HIV-1 gp120 and prevents viral attachment to the cellular CD4 receptor. Here, we review the pharmacology, efficacy, tolerability, and resistance profile of fostemsavir. Recent findings Fostemsavir is well tolerated and maintains virologic activity in individuals harboring multidrug-resistant HIV-1. In conjunction with optimal background therapy, a majority of heavily treatment-experienced clinical trial participants treated with fostemsavir achieved virologic suppression. Summary The approval of fostemsavir represents an important advance for individuals harboring multidrug resistant HIV-1 due to its novel mechanism of action and lack of cross-resistance to other antiretrovirals. Further study will better define the role of resistance testing for fostemsavir and fostemsavir's potential role outside of salvage therapy in heavily treatment-experienced individuals.

[1]  M. Kozal,et al.  Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1 , 2021, AIDS.

[2]  M. Kozal,et al.  Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. , 2020, The lancet. HIV.

[3]  M. Kozal,et al.  Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. , 2020, The New England journal of medicine.

[4]  Alon Herschhorn,et al.  Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529 , 2017, Nature chemical biology.

[5]  Samit R. Joshi,et al.  Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial , 2017, Antiviral therapy.

[6]  Samit R. Joshi,et al.  Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. , 2015, The lancet. HIV.

[7]  M. Krystal,et al.  Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. , 2012, The Journal of infectious diseases.

[8]  N. Meanwell,et al.  In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068 , 2012, Antimicrobial Agents and Chemotherapy.

[9]  M. Krystal,et al.  Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects , 2010, Antimicrobial Agents and Chemotherapy.